Array ( [0] => {{Short description|Chemical entity which can be bound by an antibody}} [1] => An '''epitope''', also known as '''antigenic determinant''', is the part of an [[antigen]] that is recognized by the [[immune system]], specifically by [[antibody|antibodies]], [[B cell]]s, or [[T cell]]s. The part of an antibody that binds to the epitope is called a [[paratope]]. Although epitopes are usually [[exogenous antigen|non-self proteins]], sequences derived from the host that can be recognized (as in the case of autoimmune diseases) are also epitopes.{{cite journal |last1=Mahmoudi Gomari |first1=Mohammad |last2=Saraygord-Afshari |first2=Neda |last3=Farsimadan |first3=Marziye |last4=Rostami |first4=Neda |last5=Aghamiri |first5=Shahin |last6=Farajollahi |first6=Mohammad M. |title=Opportunities and challenges of the tag-assisted protein purification techniques: Applications in the pharmaceutical industry |journal=Biotechnology Advances |date=1 December 2020 |volume=45 |pages=107653 |doi=10.1016/j.biotechadv.2020.107653 |pmid=33157154 |s2cid=226276355 }} [2] => [3] => The epitopes of [[protein]] antigens are divided into two categories, [[conformational epitope]]s and [[linear epitope]]s, based on their structure and interaction with the paratope.{{cite journal | vauthors = Huang J, Honda W | title = CED: a conformational epitope database | journal = BMC Immunology | volume = 7 | pages = 7 | date = April 2006 | pmid = 16603068 | pmc = 1513601 | doi = 10.1186/1471-2172-7-7 | doi-access = free }} Conformational and linear epitopes interact with the paratope based on the 3-D conformation adopted by the epitope, which is determined by the surface features of the involved epitope residues and the shape or [[tertiary structure]] of other segments of the antigen. A conformational epitope is formed by the 3-D conformation adopted by the interaction of discontiguous amino acid residues. In contrast, a linear epitope is formed by the 3-D conformation adopted by the interaction of contiguous amino acid residues. A linear epitope is not determined solely by the [[primary structure]] of the involved amino acids. Residues that flank such amino acid residues, as well as more distant amino acid residues of the antigen affect the ability of the [[primary structure]] residues to adopt the epitope's 3-D conformation.{{cite journal | vauthors = Anfinsen CB | title = Principles that govern the folding of protein chains | journal = Science | volume = 181 | issue = 4096 | pages = 223–230 | date = July 1973 | pmid = 4124164 | doi = 10.1126/science.181.4096.223 | bibcode = 1973Sci...181..223A }}{{cite journal | vauthors = Bergmann CC, Tong L, Cua R, Sensintaffar J, Stohlman S | title = Differential effects of flanking residues on presentation of epitopes from chimeric peptides | journal = Journal of Virology | volume = 68 | issue = 8 | pages = 5306–5310 | date = August 1994 | pmid = 7518534 | pmc = 236480 | doi = 10.1128/JVI.68.8.5306-5310.1994 }}{{cite journal | vauthors = Bergmann CC, Yao Q, Ho CK, Buckwold SL | title = Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes | journal = Journal of Immunology | volume = 157 | issue = 8 | pages = 3242–3249 | date = October 1996 | doi = 10.4049/jimmunol.157.8.3242 | pmid = 8871618 | s2cid = 24717835 | doi-access = free }}{{cite journal | vauthors = Briggs S, Price MR, Tendler SJ | title = Fine specificity of antibody recognition of carcinoma-associated epithelial mucins: antibody binding to synthetic peptide epitopes | journal = European Journal of Cancer | volume = 29A | issue = 2 | pages = 230–237 | date = 1993 | pmid = 7678496 | doi = 10.1016/0959-8049(93)90181-E }}{{cite journal | vauthors = Craig L, Sanschagrin PC, Rozek A, Lackie S, Kuhn LA, Scott JK | title = The role of structure in antibody cross-reactivity between peptides and folded proteins | journal = Journal of Molecular Biology | volume = 281 | issue = 1 | pages = 183–201 | date = August 1998 | pmid = 9680484 | doi = 10.1006/jmbi.1998.1907 }} 90% of epitopes are conformational.{{cite journal |last1=Ferdous |first1=Saba |last2=Kelm |first2=Sebastian |last3=Baker |first3=Terry S. |last4=Shi |first4=Jiye |last5=Martin |first5=Andrew C. R. |title=B-cell epitopes: Discontinuity and conformational analysis |journal=Molecular Immunology |date=1 October 2019 |volume=114 |pages=643–650 |doi=10.1016/j.molimm.2019.09.014 |pmid=31546099 |s2cid=202747810 |url=https://discovery.ucl.ac.uk/id/eprint/10081794/ }} [4] => [5] => ==Function== [6] => [7] => === T cell epitopes === [8] => [[T cell]] epitopes{{cite journal | vauthors = Steers NJ, Currier JR, Jobe O, Tovanabutra S, Ratto-Kim S, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M | display-authors = 6 | title = Designing the epitope flanking regions for optimal generation of CTL epitopes | journal = Vaccine | volume = 32 | issue = 28 | pages = 3509–3516 | date = June 2014 | pmid = 24795226 | doi = 10.1016/j.vaccine.2014.04.039 }} are presented on the surface of an [[antigen-presenting cell]], where they are bound to [[major histocompatibility complex]] (MHC) molecules. In humans, [[Antigen-presenting cell#Professional APCs|professional antigen-presenting cell]]s are specialized to present [[MHC class II]] peptides, whereas most nucleated [[somatic cell]]s present MHC class I peptides. T cell epitopes presented by [[MHC class I]] molecules are typically peptides between 8 and 11 amino acids in length, whereas MHC class II molecules present longer peptides, 13–17 amino acids in length,{{cite book | vauthors = Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P |title=Molecular biology of the cell |date=2002 |publisher=Garland Science |location=New York |isbn=978-0815332183 |edition=4th |page=1401 }} and non-classical MHC molecules also present non-peptidic epitopes such as [[glycolipid]]s. [9] => [10] => === B cell epitopes === [11] => The part of the antigen that immunoglobulin or antibodies bind to is called a B-cell epitope.{{cite journal |last1=Sanchez-Trincado |first1=Jose L. |last2=Gomez-Perosanz |first2=Marta |last3=Reche |first3=Pedro A. |title=Fundamentals and Methods for T- and B-Cell Epitope Prediction |journal=Journal of Immunology Research |date=2017 |volume=2017 |pages=1–14 |doi=10.1155/2017/2680160 |pmid=29445754 |pmc=5763123 |doi-access=free }} B cell epitopes can be divided into two groups: conformational or linear. B cell epitopes are mainly conformational.{{cite journal | vauthors = El-Manzalawy Y, Honavar V | title = Recent advances in B-cell epitope prediction methods | journal = Immunome Research | volume = 6 | issue = Suppl 2 | pages = S2 | date = November 2010 | pmid = 21067544 | pmc = 2981878 | doi = 10.1186/1745-7580-6-S2-S2 | doi-access = free }}{{cite book |doi=10.1007/978-1-59745-450-6_1 |chapter=What is a B-Cell Epitope? |title=Epitope Mapping Protocols |series=Methods in Molecular Biology |year=2009 |last1=Regenmortel |first1=Marc H.V. |volume=524 |pages=3–20 |pmid=19377933 |isbn=978-1934115176 }} There are additional epitope types when the quaternary structure is considered. Epitopes that are masked when protein subunits aggregate are called [[cryptotope]]s. Neotopes are epitopes that are only recognized while in a specific quaternary structure and the residues of the epitope can span multiple protein subunits. Neotopes are not recognized once the subunits dissociate. [12] => [13] => ===Cross-activity=== [14] => Epitopes are sometimes cross-reactive. This property is exploited by the immune system in regulation by anti-idiotypic antibodies (originally proposed by Nobel laureate [[Niels Kaj Jerne]]). If an antibody binds to an antigen's epitope, the paratope could become the epitope for another antibody that will then bind to it. If this second antibody is of IgM class, its binding can upregulate the immune response; if the second antibody is of IgG class, its binding can downregulate the immune response.{{citation needed|date=September 2012}} [15] => [16] => ==Epitope mapping== [17] => {{main|Epitope mapping}} [18] => [19] => === T cell epitopes === [20] => MHC class I and II epitopes can be reliably predicted by computational means alone,{{cite journal |last1=Koren |first1=E. |last2=Groot |first2=Anne De |last3=Jawa |first3=V. |last4=Beck |first4=K. |last5=Boone |first5=T. |last6=Rivera |first6=D. |last7=Li |first7=L. |last8=Mytych |first8=D. |last9=Koscec |first9=M. |last10=Weeraratne |first10=D. |last11=Swanson |first11=S. |last12=Martin |first12=W. |title=Clinical validation of the 'in silico' prediction of immunogenicity of a human recombinant therapeutic protein |journal=Institute for Immunology and Informatics Faculty Publications |date=1 January 2007 |volume=124 |issue=1 |pages=26–32 |doi=10.1016/j.clim.2007.03.544 |pmid=17490912 |s2cid=12867280 |url=https://digitalcommons.uri.edu/immunology_facpubs/69/ }} although not all in-silico T cell epitope prediction algorithms are equivalent in their accuracy.{{cite journal |last1=De Groot |first1=Anne S. |last2=Martin |first2=William |title=Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics |journal=Clinical Immunology |date=May 2009 |volume=131 |issue=2 |pages=189–201 |doi=10.1016/j.clim.2009.01.009 |pmid=19269256 }} There are two main methods of predicting peptide-MHC binding: data-driven and structure-based. Structure based methods model the peptide-MHC structure and require great computational power. Data-driven methods have higher predictive performance than structure-based methods. Data-driven methods predict peptide-MHC binding based on peptide sequences that bind MHC molecules. By identifying T-cell epitopes, scientists can track, phenotype, and stimulate T-cells.{{cite journal |last1=Peters |first1=Bjoern |last2=Nielsen |first2=Morten |last3=Sette |first3=Alessandro |title=T Cell Epitope Predictions |journal=Annual Review of Immunology |date=26 April 2020 |volume=38 |issue=1 |pages=123–145 |doi=10.1146/annurev-immunol-082119-124838 |pmid=32045313 |s2cid=211085860 |pmc=10878398 }}{{cite journal |last1=Ahmad |first1=Tarek A. |last2=Eweida |first2=Amrou E. |last3=El-Sayed |first3=Laila H. |title=T-cell epitope mapping for the design of powerful vaccines |journal=Vaccine Reports |date=December 2016 |volume=6 |pages=13–22 |doi=10.1016/j.vacrep.2016.07.002 }} [21] => [22] => === B cell epitopes === [23] => There are two main methods of epitope mapping: either structural or functional studies.{{cite journal |last1=Potocnakova |first1=Lenka |last2=Bhide |first2=Mangesh |last3=Pulzova |first3=Lucia Borszekova |title=An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction |journal=Journal of Immunology Research |date=2016 |volume=2016 |pages=1–11 |doi=10.1155/2016/6760830 |pmid=28127568 |pmc=5227168 |doi-access=free }} Methods for structurally mapping epitopes include [[X-ray crystallography]], [[nuclear magnetic resonance]], and [[Electron microscope|electron microscopy]]. X-ray crystallography of Ag-Ab complexes is considered an accurate way to structurally map epitopes. Nuclear magnetic resonance can be used to map epitopes by using data about the Ag-Ab complex. This method does not require crystal formation but can only work on small peptides and proteins. Electron microscopy is a low-resolution method that can localize epitopes on larger antigens like virus particles. [24] => [25] => Methods for functionally mapping epitopes often use binding assays such as [[western blot]], [[dot blot]], and/or [[ELISA]] to determine antibody binding. Competition methods look to determine if two [[Monoclonal antibody|monoclonal antibodies]] (mABs) can bind to an antigen at the same time or compete with each other to bind at the same site. Another technique involves high-throughput [[mutagenesis]], an epitope mapping strategy developed to improve rapid mapping of conformational epitopes on structurally complex proteins.{{cite journal |last1=Davidson |first1=Edgar |last2=Doranz |first2=Benjamin J. |title=A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes |journal=Immunology |date=September 2014 |volume=143 |issue=1 |pages=13–20 |doi=10.1111/imm.12323 |pmid=24854488 |pmc=4137951 }} Mutagenesis uses randomly/site-directed mutations at individual residues to map epitopes. B-cell epitope mapping can be used for the development of antibody therapeutics, peptide-based vaccines, and immunodiagnostic tools.{{cite journal |last1=Ahmad |first1=Tarek A. |last2=Eweida |first2=Amrou E. |last3=Sheweita |first3=Salah A. |title=B-cell epitope mapping for the design of vaccines and effective diagnostics |journal=Trials in Vaccinology |date=2016 |volume=5 |pages=71–83 |doi=10.1016/j.trivac.2016.04.003 |doi-access=free }}   [26] => [27] => ==Epitope tags== [28] => [29] => Epitopes are often used in [[proteomics]] and the study of other gene products. Using [[recombinant DNA]] techniques genetic sequences coding for epitopes that are recognized by common antibodies can be fused to the gene. Following [[Protein biosynthesis|synthesis]], the resulting epitope tag allows the antibody to find the protein or other gene product enabling lab techniques for localisation, purification, and further molecular characterization. Common epitopes used for this purpose are [[Myc-tag]], [[HA-tag]], [[FLAG-tag]], [[GST-tag]], [[Polyhistidine-tag|6xHis]],{{cite book |title= Molecular bio-methods handbook| vauthors = Walker J, Rapley R |year= 2008|publisher= Humana Press |isbn= 978-1603273749|page=467}} V5-tag and OLLAS.{{cite web|last=Novus|first=Biologicals|title=OLLAS Epitope Tag|url=http://www.novusbio.com/ollas|publisher=Novus Biologicals|access-date=23 November 2011}} Peptides can also be bound by proteins that form covalent bonds to the peptide, allowing irreversible immobilisation.{{cite journal | vauthors = Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M | title = Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 109 | issue = 12 | pages = E690–697 | date = March 2012 | pmid = 22366317 | pmc = 3311370 | doi = 10.1073/pnas.1115485109 | bibcode = 2012PNAS..109E.690Z | doi-access = free }} These strategies have also been successfully applied to the development of "epitope-focused" vaccine design.{{cite journal | vauthors = Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE, Johnson PR, Schief WR | display-authors = 6 | title = Proof of principle for epitope-focused vaccine design | journal = Nature | volume = 507 | issue = 7491 | pages = 201–206 | date = March 2014 | pmid = 24499818 | pmc = 4260937 | doi = 10.1038/nature12966 | bibcode = 2014Natur.507..201C }}{{cite journal | vauthors = McBurney SP, Sunshine JE, Gabriel S, Huynh JP, Sutton WF, Fuller DH, Haigwood NL, Messer WB | display-authors = 6 | title = Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates | journal = Vaccine | volume = 34 | issue = 30 | pages = 3500–3507 | date = June 2016 | pmid = 27085173 | pmc = 4959041 | doi = 10.1016/j.vaccine.2016.03.108 | author-link7 = Nancy Haigwood }} [30] => [31] => == Epitope-based vaccines == [32] => {{Main articles|Peptide vaccine}} [33] => The first epitope-based vaccine was developed in 1985 by Jacob et al.{{cite journal |last1=Parvizpour |first1=Sepideh |last2=Pourseif |first2=Mohammad M. |last3=Razmara |first3=Jafar |last4=Rafi |first4=Mohammad A. |last5=Omidi |first5=Yadollah |title=Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches |journal=Drug Discovery Today |date=June 2020 |volume=25 |issue=6 |pages=1034–1042 |doi=10.1016/j.drudis.2020.03.006 |pmid=32205198 |s2cid=214629963 }} Epitope-based vaccines stimulate [[Humoral immunity|humoral]] and [[Cell-mediated immunity|cellular immune]] responses using isolated B-cell or T-cell epitopes. These vaccines can use multiple epitopes to increase their efficacy. To find epitopes to use for the vaccine, [[in silico]] mapping is often used. Once candidate epitopes are found, the constructs are engineered and tested for vaccine efficiency. While epitope-based vaccines are generally safe, one possible side effect is cytokine storms.   [34] => [35] => ==Neoantigenic determinant== [36] => A '''neoantigenic determinant''' is an epitope on a [[neoantigen]], which is a newly formed [[antigen]] that has not been previously recognized by the immune system.{{cite book | vauthors = Hans-Werner V |date=2005 |chapter=Neoantigen-Forming Chemicals | title = Encyclopedic Reference of Immunotoxicology |page=475 |doi=10.1007/3-540-27806-0_1063|isbn=978-3540441724 }} Neoantigens are often associated with [[tumor antigen]]s and are found in oncogenic cells.Neoantigen. (n.d.) Mosby's Medical Dictionary, 8th edition. (2009). Retrieved February 9, 2015 from [http://medical-dictionary.thefreedictionary.com/neoantigen Medical Dictionary Online] Neoantigens and, by extension, neoantigenic determinants can be formed when a protein undergoes further modification within a biochemical pathway such as [[glycosylation]], [[phosphorylation]] or [[proteolysis]]. This, by altering the structure of the protein, can produce new epitopes that are called neoantigenic determinants as they give rise to new [[antigenic determinants]]. Recognition requires separate, specific [[antibodies]].{{cn|date=November 2023}} [37] => [38] => == See also == [39] => * [[Cryptotope]] [40] => * [[Epitope binning]] [41] => * [[Mimotope]] [42] => * [[Odotope]] [43] => * [[Polyclonal B cell response]] [44] => * [[Protein tag]] [45] => * [[TimeSTAMP protein labelling]] [46] => [47] => == References == [48] => {{Reflist}} [49] => [50] => == External links == [51] => * [https://www.ncbi.nlm.nih.gov/books/bv.fcgi?highlight=epitope&rid=imm.section.335#341 Antibodies bind to conformational shapes on the surfaces of antigens (Janeway Immunobiology Section 3.8)] [52] => * [https://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=imm.figgrp.340 Antigens can bind in pockets or grooves, or on extended surfaces in the binding sites of antibodies (Janeway Immunobiology Figure 3.8)] [53] => [54] => ===Epitope prediction methods=== [55] => {{refbegin}} [56] => * {{cite journal | vauthors = Rubinstein ND, Mayrose I, Martz E, Pupko T | title = Epitopia: a web-server for predicting B-cell epitopes | journal = BMC Bioinformatics | volume = 10 | pages = 287 | date = September 2009 | pmid = 19751513 | pmc = 2751785 | doi = 10.1186/1471-2105-10-287 | doi-access = free }} [57] => * {{cite journal | vauthors = Rubinstein ND, Mayrose I, Pupko T | title = A machine-learning approach for predicting B-cell epitopes | journal = Molecular Immunology | volume = 46 | issue = 5 | pages = 840–847 | date = February 2009 | pmid = 18947876 | doi = 10.1016/j.molimm.2008.09.009 }} [58] => * {{cite journal | vauthors = Saravanan V, Gautham N | title = Harnessing Computational Biology for Exact Linear B-Cell Epitope Prediction: A Novel Amino Acid Composition-Based Feature Descriptor | journal = Omics | volume = 19 | issue = 10 | pages = 648–658 | date = October 2015 | pmid = 26406767 | doi = 10.1089/omi.2015.0095 }} [59] => * {{cite journal | vauthors = Singh H, Ansari HR, Raghava GP | title = Improved method for linear B-cell epitope prediction using antigen's primary sequence | journal = PLOS ONE | volume = 8 | issue = 5 | pages = e62216 | date = 2013 | pmid = 23667458 | pmc = 3646881 | doi = 10.1371/journal.pone.0062216 | bibcode = 2013PLoSO...862216S | doi-access = free }} [60] => {{refend}} [61] => [62] => ===Epitope databases=== [63] => * [http://www.imtech.res.in/raghava/mhcbn/ MHCBN: A database of MHC/TAP binder and T-cell epitopes] [64] => * [http://www.imtech.res.in/raghava/bcipep/ Bcipep: A database of B-cell epitopes] [65] => * [http://www.syfpeithi.de SYFPEITHI – First online database of T cell epitopes] [66] => * [http://www.immuneepitope.org IEDB – Database of T and B cell epitopes with annotation of recognition context – NIH funded] [67] => * [https://web.archive.org/web/20060902162039/http://www.jenner.ac.uk/antijen/ ANTIJEN – T and B cell epitope database at the Jenner institute, UK] [68] => * [https://web.archive.org/web/20061006031248/http://imgt.cines.fr/ IMGT/3Dstructure-DB – Three-dimensional structures of B and T cell epitopes with annotation of IG and TR – IMGT, Montpellier, France] [69] => * [http://sedb.bicpu.edu.in/ SEDB: A Structural Epitope Database – Pondicheery University, DIT funded] [70] => * {{MeshName|Epitopes}} [71] => {{Immune system}} [72] => {{Authority control}} [73] => [74] => [[Category:Antigenic determinant|*]] [75] => [76] => [[it:Antigene#Epitopo]] [] => )
good wiki

Epitope

An epitope, also known as antigenic determinant, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. The part of an antibody that binds to the epitope is called a paratope.

More about us

About

Expert Team

Vivamus eget neque lacus. Pellentesque egauris ex.

Award winning agency

Lorem ipsum, dolor sit amet consectetur elitorceat .

10 Year Exp.

Pellen tesque eget, mauris lorem iupsum neque lacus.

You might be interested in

Antibodies

Antibody

An antibody, also known as an immunoglobulin, is a large Y-shaped protein produced by the immune system to neutralize pathogens such as bacteria and viruses.

Antigen

An antigen is a substance that triggers an immune response in the body.

ELISA

ELISA (enzyme-linked immunosorbent assay) is a widely used laboratory technique used to detect and quantify the presence of specific proteins, antibodies, or antigens in a sample.

Glycosylation

Glycosylation is the reaction in which a carbohydrate (or 'glycan'), i.

Protein

Proteins are macromolecules found in all living organisms.

Proteomics

Proteomics is the large-scale study of proteins.